vTv Therapeutics Inc. (NASDAQ:VTVT) Given Consensus Rating of “Moderate Buy” by Analysts

Posted by Brian Himes on Jun 11th, 2026

vTv Therapeutics Inc. (NASDAQ:VTVT – Get Free Report) has earned a consensus rating of “Moderate Buy” from the seven analysts that are currently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, five have assigned a buy rating and one has issued a strong buy rating on the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $53.00.

A number of research analysts have recently commented on VTVT shares. Zacks Research raised vTv Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Wednesday, May 13th. Evercore started coverage on vTv Therapeutics in a report on Thursday, March 12th. They set an “outperform” rating and a $44.00 price target on the stock. Wall Street Zen raised vTv Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, May 16th. Weiss Ratings raised vTv Therapeutics from a “sell (d-)” rating to a “sell (d+)” rating in a report on Monday, May 18th. Finally, BTIG Research reissued a “buy” rating and set a $49.00 price target on shares of vTv Therapeutics in a report on Wednesday, March 11th.

Get Our Latest Analysis on VTVT

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Baker BROS. Advisors LP boosted its stake in vTv Therapeutics by 52.4% during the third quarter. Baker BROS. Advisors LP now owns 148,314 shares of the biotechnology company’s stock valued at $3,463,000 after buying an additional 51,000 shares in the last quarter. Goldman Sachs Group Inc. bought a new position in vTv Therapeutics during the fourth quarter valued at about $221,000. Geode Capital Management LLC boosted its stake in vTv Therapeutics by 84.3% during the fourth quarter. Geode Capital Management LLC now owns 28,194 shares of the biotechnology company’s stock valued at $1,128,000 after buying an additional 12,896 shares in the last quarter. Finally, 683 Capital Management LLC bought a new position in vTv Therapeutics during the fourth quarter valued at about $731,000. Institutional investors own 17.51% of the company’s stock.

vTv Therapeutics Stock Performance

Shares of VTVT opened at $30.44 on Thursday. The firm has a market capitalization of $119.90 million, a price-to-earnings ratio of -32.73 and a beta of 0.27. vTv Therapeutics has a one year low of $14.00 and a one year high of $44.00. The stock’s fifty day moving average is $35.02 and its 200-day moving average is $35.04.

vTv Therapeutics (NASDAQ:VTVT – Get Free Report) last issued its quarterly earnings results on Wednesday, May 13th. The biotechnology company reported $1.65 EPS for the quarter, beating analysts’ consensus estimates of $0.21 by $1.44. The business had revenue of $36.84 million for the quarter, compared to analyst estimates of $20.00 million. Analysts forecast that vTv Therapeutics will post -2.19 EPS for the current fiscal year.

About vTv Therapeutics

(Get Free Report)

vTv Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Westport, Connecticut, focused on discovering and developing orally administered small-molecule therapies for chronic diseases. Employing its proprietary medicinal chemistry platform, the company seeks to generate novel compounds that modulate key disease pathways while optimizing safety and pharmacokinetic properties.

The company’s lead candidate, azeliragon (TTP488), is an oral inhibitor of the receptor for advanced glycation end products (RAGE) and has completed Phase II/III clinical evaluation in early-stage Alzheimer’s disease.